Vitaherpavac, a dry inactivated herpes simplex virus (HSV) culture vaccine, has been obtained, by using the Vero B continuous cell line as a substrate for accumulation of herpes simplex virus types 1 (US strain) and 2 (VN strain). Vitaherpavac and the similar vaccine Herpovax made by the Research Institute of Vaccines and Sera, Saint Petersburg (for which preparation a primary trypsinized chick embryo cell culture used as a substrate for accumulation of HSV types 1 and 2), underwent comparative clinical trials. The tolerability and therapeutic effectiveness of the vaccine were tested in patients diagnosed as having chronic frequently recurring herpes. The trials have yielded positive results that suggest that it is expedient to introduce of the new vaccine Vitaherpavac into practice to treat chronic recurrent herpetic infection of various localizations. Vitaherpavac has been registered in the Russian Federation and permitted for medical application.

The quality of drugs used in the Russian Federation to prevent and diagnose tick-borne encephalitis (TBE) was analyzed. The TBE vaccines made in Russian were shown to be as effective as those manufactured in foreign countries and to have the similar production techniques and quality indices therefore they may be interchangeable in the population's vaccination. The specific activity of has recently increased in terms of the content of TBE virus antibodies. In Russia, a wide range of enzyme immunoassay systems have been designed and manufactured for the detection of human serum (plasma) IgM and IgG antibodies to TVE virus and for that of TBE viral antigen in the biological objects, primarily in the ticks.

Inactivated culture vaccine against tick-borne encephalitis (TBE) FSME-Immun-Inject produced in Austria ("Immuno") was compared to vaccine produced in the Institute of Poliomyelitis and viral encephalitis by immunological activity, safety, reactogenicity. In mice, no significant differences in protective activity of the vaccines were found when test-strains were diverse strains of TBE virus. Seroconversion in the sera from the vaccinated two times was not significantly different by the level of antibodies determined for both eastern and western serotypes of TBE virus.

The paper presents the results of the study of 8 attenuated strains of viruses of the tick-borne encephalitis complex by the marker of pathogenicity for Syrian hamsters in comparison with virulent virus strains. The group of the attenuated strains was found to be nonhomogeneous in this marker of pathogenicity for Syrian hamsters. One of the 8 strains, Pan-114, proved to be highly virulent for these animals by the intracerebral route. The analysis of the experimental results and data from the literature shows the degree of pathogenicity of attenuated strains to differ for mice, Syrian hamsters and monkeys, apparently indicating that each virus variant is attenuated only for a given species of laboratory animals.